Citations

Showing 10 of 108104 citations.

CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)
Tella, Sri Harsha , Wessling, Jaclynn, Nathan, Foster, Qian, Shi, Nguyen, Tran, McWillimas, Robert, Steven, Alberts, Liu, Minetta C. , Hartgers, Mindy L., Washburn, Leslie, Briant, Fruth, Fernández-Zapico, Martín E. , Hogenson, Tara L. , Pitot, Henry C., Qian, Shi, Borad, Mitesh J. , Wee, Wen , Jin, Zhaohui , Mahipal, Amit

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: CLO22-088

10.6004/jnccn.2021.7328 Get It

QIM22-194: Using the Merlin Assay to Reduce Sentinel Lymph Node Biopsy Rates and Its Complications: A Retrospective Cohort Study
Sadurní, Mariana B. , Quattrocchi, Enrica , Kobic, Ajdin, Sominidi‐Damodaran, Sindhuja , Meerstein, Lisette, Dwarkasing, Jvalini, Bridges, Alina G. , Meves, Alexander , Hieken, Tina J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: QIM22-194

10.6004/jnccn.2021.7223 Get It

HSR22-126: Key Factors Associated With Breast Cancer Clinical Trial Enrollment in Underrepresented Minority Groups
Baksh, Mizba , Hochwald, Alexander , David, Hodge, Advani, Pooja , Spaulding, Aaron , Ailawadhi, Sikander

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: HSR22-126

10.6004/jnccn.2021.7195 Get It

CLO22-067: Symptom Burden in Patients With Myelofibrosis who Have Moderate or Severe Thrombocytopenia: A Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study
Palmer, Jeanne , Rampal, Raajit K. , Buckley, Sarah , Roman‐Torres, Karisse, Mesa, Ruben A. , Bose, Prithviraj , Oh, Stephen T. , Verstovšek, Srđan , Mascarenhas, John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: CLO22-067

10.6004/jnccn.2021.7287 Get It

BPI22-021: Surveillance Mammography in Elderly Breast Cancer Survivors (Project Funded by Breast Cancer Research Foundation)
Karam, Dhauna , Ehlers, Shawna L. , Choudhery, Sadia, Larson, Nicole L. , Loprinzi, Charles L. , Ruddy, Kathryn J. , Vierkant, Robert A. , Freedman, Rachel A. , Austin, Jessica D. , Olson, Janet E. , Couch, Fergus J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: BPI22-021

10.6004/jnccn.2021.7167 Get It

Comparison of 2-days and 7-days of prophylactic antibiotic therapy in the prevention of surgical site infection in coronary artery bypass grafting: A randomized, double-blind placebo-controlled trial
Barary, Mohammad , Ganji, Ghasem Faghanzadeh , Aliramaji, Zahra, Ebrahimpour, Soheil , Roushan, Mohammad Reza Hasanjani , Zavareh, Mahmoud Sadeghi Haddad , Vafaei, Hamid Reza, Barary, Mohammad , Sio, Terence T. , Bayani, Masomeh , Koppolu, Veerendra , Javanian, Mostafa

Mayo Clinic

No container title available | March 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.164873530.04730128/v1 Get It

Objectives: The current study aimed to compare the efficacy of the two different prophylactic antibiotic regimens (2-days vs. 7-days) in preventing surgical site infection in coronary artery bypass grafting (CABG). Methods : Patients undergoing CABG were included in this randomized, double-blind, placebo-controlled trial. From 2016 to 2017, 370 cases were allocated to one of two groups. The groups received prophylactic antibiotic therapy for either 2-days or 7-days. All CABG patients were followed for days for surgical site infections. Two of the patients died after surgery, and 3 patients did not show up during the three-month follow-up evaluation and thus did not meet the study criteria. Results: Of the remaining 365 patients who participated in the full study, 198 (54.2%) were male, and 167 (45.7%) were female patients. The mean age of these cases was 58.64± 11.4. Of the 365 study participants who received prophylactic antibiotics prior to surgery, 16 patients developed surgical site infections (legs and sternum). Among these 16 patients, nine cases belong to the 7-days prophylactic antibiotic therapy group (2.4%), and seven cases belong to the 2-day prophylactic antibiotic therapy group (1.9%) (P=0.771). Conclusion: Comparison of two 2-day and 7-day prophylactic antibiotic regimens showed no significant difference in the incidence of post-surgical infection in the two groups.
Rare adverse events following Covid-19 vaccination: A review
Barary, Mohammad , Afshar, Zeinab Mohseni , Liang, Jackson J. , Sharma, Akanksha , Hashemi, Erfan , Abdi, Sadaf, Allahgholipour, Amirreza , Hosseinzadeh, Rezvan , Vaziri, Zahra , Ebrahimpour, Soheil , Barary, Mohammad , Liang, Jackson , Afshar, Zeinab Mohseni , Pirzadeh, Marzieh , Babazadeh, Arefeh , Deravi, Niloofar , Sio, Terence T. , Sullman, Mark J. M.

Mayo Clinic

No container title available | March 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.164873369.97865492/v1 Get It

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused many complications, the invention of coronavirus disease 2019 (Covid-19) vaccines has also brought about several adverse events, from common side effects to unexpected and rare ones. Common vaccine-related adverse reactions manifest locally or systematically following any vaccine, including Covid-19 vaccines. Certain side effects, known as adverse events of special interest (AESI), are unusual and need more evaluation. Here, we discuss some of the most important rare adverse events of Covid-19 vaccines.
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
Shropshire, William C. , Dinh, An Q , Earley, Michelle, Komarow, Lauren , Panesso, Diana , Rydell, Kirsten, Gómez-Villegas, Sara I, Miao, Hongyu , Hill, Carol , Chen, Liang , Patel, Robin , Abbo, Lilian M. , Cober, Eric , Revolinski, Sara , Luterbach, Courtney , Chambers, Henry F. , Fowler, Vance G. , Shelburne, Samuel A. , Kreiswirth, Barry N. , Hanson, Blake , Arias, César A. , Revolinski, Sara , Bonomo, Robert A , Shelburne, Samuel A , Kreiswirth, Barry N , van Duin, David , Hanson, Blake M , Chen, Liang , Patel, Robin , Abbo, Lilian M , Fries, Bettina C. , Fowler, Vance G. , Bonomo, Robert A. , Arias, César A.

Mayo Clinic

mBio | March 31, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.00497-22 | PMID 35357213 Get It

The prevalence of carbapenem-resistant Klebsiella pneumoniae (CR Kp ) infections in nosocomial settings remains a public health challenge. High-risk clones such as clonal group 258 (CG258) are particularly concerning due to their association with bla KPC carriage, which can severely complicate antimicrobial treatments.
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Borlaug, Barry A. , Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Daniel , Bruch, Leonhard , Celermajer, David S. , Claggett, Brian , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Gustafsson, Finn , Heyden, Jan van der, Hasenfuß, Gerd, Hummel, Scott L. , Komtebedde, Jan, Mazurek, Jeremy A., McKenzie, Scott , Mehta, Shamir R. , Petrie, Mark C. , Post, Marco C., Nair, Ajith, Rieth, Andreas , Silvestry, Frank E., Solomon, Scott D. , Trochu, Jean‐Noël , Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II, Bugger, Heiko , Nair, Ajith , Burkhoff, Daniel , Hayward, Chris , Hummel, Scott L , Kaye, David M , Massaro, Joseph M. , McKenzie, Scott , Mehta, Shamir R , Petrie, Mark C , Rieth, Andreas , Solomon, Scott David , Trochu, Jean-Noël , Shah, Sanjiv J , Borlaug, Barry A , Nair, Ajith P , Celermajer, David , Gustafsson, Finn , Blair, John, Bergmann, Martin W., Bruch, Leonhard , Claggett, Brian L , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Heyden, Jan van der, Hasenfuß, Gerd, Komtebedde, Jan, Mazurek, Jeremy A., Post, Marco C., Nair, Ajith, Silvestry, Frank E., Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II

Mayo Clinic

Circulation | March 31, 2022 | Volume: 145 | Issue: 21 | Pages: 1592-1604

10.1161/circulationaha.122.059486 | PMID 35354306 Get It

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome—a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status—was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004). Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.
Is MIS-C (Multisystem Inflammatory Syndrome in Children) a Vaccine-Preventable Disease?
Mangat, Chetna , Milosavljevic, Natasa

Mayo Clinic

Clinical Pediatrics | March 31, 2022 | Volume: 61 | Issue: 5-6 | Pages: 402-403

10.1177/00099228221083894 | PMID 35357249 Get It